RIC Regimen for Low- and Intermediate-risk MDS Receiving Haplo-HSCT
Status:
Recruiting
Trial end date:
2022-03-01
Target enrollment:
Participant gender:
Summary
This study aimed to evaluate the efficacy of reduced intensity conditioning (RIC) regimen in
low- and intermediate-risk myelodysplastic syndrome (MDS) patients who receive haploidentical
hematopoietic stem cell transplantation (haplo-HSCT). Haplo-HSCT is an effective treatment
option for MDS patients who did not have identical sibling donor (ISD) or unrelated donor
(URD). However, post-transplant transplant-related mortality (TRM) is one of the major causes
for transplant failure in MDS patients, and the risk of TRM for haplo-HSCT recipients was
higher than that of ISD recipients. RIC regimen can decrease the risk of TRM for haplo-HSCT
recipients; however, the risk for relapse may increase in these patients. Thus, RIC regimen
may be more appropriate for low- and intermediate-risk MDS patients receiving haplo-HSCT. The
study hypothesis: Using RIC haplo-HSCT regimen in patients with low- and risk MDS can reduce
TRM and improve survival.